Perspective Therapeutics (CATX) EBITDA Margin (2010 - 2023)

Perspective Therapeutics (CATX) has 14 years of EBITDA Margin data on file, last reported at 238.19% in Q4 2023.

• For the quarter ending Q4 2023, EBITDA Margin changed N/A year-over-year to 238.19%; the trailing twelve-month figure through Dec 2023 stood at 4839.36% (changed N/A YoY), and the FY2023 full-year result was 2855.02%, changed N/A from the prior year.
• EBITDA Margin improved to 238.19% in Q4 2023, from 446.22% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 238.19% in Q4 2023 to a low of 650.27% in Q2 2023.
• A 5-year average of 105.92% and a median of 52.17% in 2020 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin surged 10184 bps in 2021 and sank 58596 bps in 2023, its largest moves.
• Tracing CATX's EBITDA Margin over 5 years: stood at 40.93% in 2019, then rose by 10 bps to 37.01% in 2020, then sank by 57 bps to 58.06% in 2021, then plunged by 86 bps to 107.82% in 2022, then soared by 321 bps to 238.19% in 2023.
• Business Quant data shows CATX's EBITDA Margin at 238.19% in Q4 2023, 446.22% in Q3 2023, and 650.27% in Q2 2023.